The Cancer Patient and Cardiology.

Advances in cancer treatment have improved clinical outcomes, leading to an increasing population of cancer survivors. Yet, this success is associated with high rates of short- and long-term cardiovascular (CV) toxicities. The number and variety of cancer drugs and CV toxicity types make long-term care a complex undertaking. This requires a multidisciplinary approach including expertise from oncology, cardiology, and other related specialties, and has led to the development of the cardio-oncology subspecialty. This paper aims to provide an overview of the main adverse events, risk assessment and risk mitigation strategies, early diagnosis, medical and complementary strategies for prevention and management, and long-term follow-up strategies for patients at risk of cancer therapy-related cardiotoxicities. Research is highly needed to better define strategies for early identification, follow-up, and management. While the academic cardio-oncology community may be the best vehicle to foster awareness and research in this field, additional stakeholders (industry, government agencies, and patient organizations) have to be involved to facilitate cross-disciplinary interactions and help in the design and funding of cardio-oncology trials. The overarching goal of cardio-oncology is to assist clinicians in providing optimal care for patients with cancer and for cancer survivors, to provide insight into future areas of research and to search for collaborations with industry, funding bodies, and patient advocates. However, many unmet needs remain. This document is the product of brainstorming presentations and active discussions held at the Cardiovascular Round Table (CRT) workshop organised in January 2020 by the European Society of Cardiology (ESC). This article is protected by copyright. All rights reserved.